Type 2 diabetes treatment: choosing drugs by the patient, not only by glucose
- Follow-up and treatment
Some diabetes drugs protect the heart and kidneys, others mainly lower sugar. Choosing by the patient's organs saves more lives than chasing a number.
See it in 3D: Pancreas
What it is
Treatment of type 2 diabetes rests on lifestyle change (food, activity, sleep, weight) plus medicines chosen in two layers. The first layer asks which organs need protecting: in established atherosclerotic cardiovascular disease or high cardiovascular risk, heart failure or chronic kidney disease, an SGLT2 inhibitor and/or a GLP-1 receptor agonist with proven benefit is started whatever the HbA1c and whether or not metformin is already used. The second layer reaches the individual glucose target while weighing weight effect, hypoglycaemia risk, side effects, the patient's preferences and cost. Metformin remains the usual first drug for most patients without these conditions because it is effective, cheap, weight-neutral and rarely causes hypoglycaemia. Insulin is started early when there is weight loss with ketosis, symptomatic or very high glucose, or when other drugs are not enough.
What to know
- Lifestyle is treatment, not a preliminary: weight loss of a meaningful fraction of body weight can bring some people with recent type 2 diabetes into remission.
- Atherosclerotic cardiovascular disease or high risk: a GLP-1 receptor agonist or an SGLT2 inhibitor with proven cardiovascular benefit.
- Heart failure (reduced or preserved ejection fraction): an SGLT2 inhibitor reduces hospitalisation and death.
- Chronic kidney disease with albuminuria or reduced eGFR: an SGLT2 inhibitor slows kidney decline even when its glucose-lowering effect fades at low eGFR; a GLP-1 receptor agonist is an alternative or addition.
- Weight: GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide cause the most weight loss; SGLT2 inhibitors modest loss; metformin and DPP-4 inhibitors neutral; sulfonylureas, thiazolidinediones and insulin cause gain.
- Hypoglycaemia comes almost only from insulin and sulfonylureas (and meglitinides); the other classes do not cause it alone.
- Low cost: metformin, sulfonylureas, pioglitazone and human insulin; in many health systems newer classes are restricted to patients with organ indications.
- Start two drugs together when HbA1c is well above target; start insulin at once with catabolic features (weight loss, ketosis) or very high glucose.
- Treatment is reviewed every three to six months: a drug that does not help is stopped, not just added to.
- Blood pressure, a statin for most adults aged 40–75, and stopping smoking protect the large arteries as much as glucose control does.
Glucose-lowering classes: organ benefit, weight, hypoglycaemia and main safety issue
| Class | Heart and kidney | Weight | Hypoglycaemia | Main safety issue |
|---|---|---|---|---|
| Metformin | Neutral to possible benefit | Neutral or slight loss | Very low | Stomach upset; vitamin B12 deficiency; avoid at very low eGFR |
| SGLT2 inhibitors | Benefit in heart failure and kidney disease; cardiovascular benefit | Loss | Very low | Genital infections, volume depletion, euglycaemic ketoacidosis |
| GLP-1 receptor agonists | Cardiovascular benefit; kidney benefit | Marked loss | Very low | Nausea, vomiting; gallbladder disease; avoid with medullary thyroid cancer or MEN2 history |
| DPP-4 inhibitors | Neutral | Neutral | Very low | Rare pancreatitis and joint pain; some members raise heart-failure admissions |
| Thiazolidinediones (pioglitazone) | Possible stroke benefit; worsens heart failure | Gain | Very low | Fluid retention, heart failure, fractures |
| Sulfonylureas | Neutral | Gain | High | Hypoglycaemia, especially in older people and kidney failure |
| Insulin | Neutral | Gain | Highest | Hypoglycaemia; needs education and monitoring |
In the clinic
- A patient with a previous myocardial infarction and an HbA1c already at target still gains from a GLP-1 receptor agonist or an SGLT2 inhibitor: the indication is the heart, not the glucose.
- In older or frail patients, avoiding hypoglycaemia matters more than a low HbA1c: prefer classes that do not cause it and simplify treatment.
- GLP-1 receptor agonists are not combined with DPP-4 inhibitors: they act on the same pathway and add nothing.
- Before surgery or when a patient stops eating and drinking, SGLT2 inhibitors are paused because of euglycaemic ketoacidosis (see diabetes in hospital).
Next step / Initial management
- At diagnosis: HbA1c, creatinine with eGFR, urine albumin-to-creatinine ratio, lipids, liver tests and an ECG when indicated, to find the organs to protect.
- Start lifestyle change plus metformin in most patients; add an SGLT2 inhibitor or GLP-1 receptor agonist for heart failure, kidney or atherosclerotic disease regardless of HbA1c.
- Recheck HbA1c every three months until at target, then every six; intensify, switch or deprescribe at each review.
- Check eGFR and vitamin B12 periodically on metformin; review hypoglycaemia at every visit on sulfonylureas or insulin.
- Refer to endocrinology when targets are not reached despite combination therapy, when the type of diabetes is in doubt, in pregnancy, or when insulin must be started and local support is lacking.
Common traps
- Metformin must always come first: in heart failure, kidney disease or atherosclerotic disease, the protective classes are started regardless of metformin because their benefit is independent of it.
- An SGLT2 inhibitor is pointless once eGFR is low: its glucose effect fades, but kidney and heart protection persist down to low eGFR, which is why it is continued.
- A normal HbA1c means no new drug is needed: the cardiovascular and kidney indications are organ indications, not glucose indications.
- Sulfonylureas are a safe add-on for anyone: they cause prolonged hypoglycaemia in older people and in kidney failure, so other classes are preferred there.
- Adding drugs is how treatment intensifies: a drug that has not helped should be stopped, because each class adds cost, side effects and interactions.
Test yourself
Think of the answer, then tap the question to see it.
A 62-year-old with type 2 diabetes and heart failure with reduced ejection fraction has an HbA1c of 6.8% on metformin. Which class do you add and why?
An SGLT2 inhibitor: it lowers heart-failure hospitalisation and death independently of glucose, so the indication is the heart, not the HbA1c.
An 80-year-old living alone, on a sulfonylurea, has an HbA1c of 6.3% and falls at night. What is the problem and what do you change?
Overtreatment with hypoglycaemia: relax the target and replace the sulfonylurea with a class that does not cause hypoglycaemia.
A woman with type 2 diabetes, obesity and a previous stroke asks for the drug that helps both weight and arteries. Which class fits?
A GLP-1 receptor agonist with proven cardiovascular benefit: it gives marked weight loss and reduces major cardiovascular events.
Why is pioglitazone avoided in a patient with leg oedema and heart failure?
Thiazolidinediones make the kidney retain sodium and water, which worsens oedema and can precipitate heart failure.
Elsewhere in DurgiPedia
- Type 2 diabetes
- Physiology of diabetes and ketoacidosis
- Islets and insulin: secretion and actions
- Insulin signalling
Connections
See it in 3D1
The structures of Durgical's 3D anatomy where it is found.
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Type 2 Diabetes (StatPearls (NCBI Bookshelf), 2023); Metformin (StatPearls (NCBI Bookshelf), 2023); Sodium-Glucose Transport 2 (SGLT2) Inhibitors (StatPearls (NCBI Bookshelf), 2025); Glucagon-Like Peptide-1 Receptor Agonists (StatPearls (NCBI Bookshelf), 2024); Sulfonylureas (StatPearls (NCBI Bookshelf), 2023); Thiazolidinediones (StatPearls (NCBI Bookshelf), 2023).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
